Aim: To provide expert consensus on the clinical indicators that signal a person with a haematological malignancy is at high risk of deteriorating and dying.
| INTRODUCTION
Haematological malignancies are a collection of heterogeneous neoplasms that originate in cells of the bone marrow and lymphatic system (Rodriguez-Abreu, Bordoni, & Zucca, 2007) . This includes diseases such as acute and chronic leukaemia, Hodgkin and nonHodgkin lymphoma, and multiple myeloma. Collectively, haematological malignancies are the sixth most commonly diagnosed cancers in the world (Ferlay et al., 2015) .
| Background
A significant body of international literature highlights there are challenges providing palliative and end-of-life care in the specialty area of clinical malignant haematology (Moreno-Alonso et al., 2017) . People with a haematological malignancy often experience a fluctuating and unpredictable illness trajectory and can deteriorate rapidly to a terminal event (Hung et al., 2013; Manitta, Philip, & Cole-Sinclair, 2010; McGrath & Holewa, 2007) . There can be hope for long-term survival or cure in the presence of critical illness or advanced disease (LeBlanc et al., 2015; Odejide, Salas Coronado, Watts, Wright, & Abel, 2014) . For these reasons, prognosticating is difficult for people with a haematological malignancy, leading to delays in identification of dying and problems transitioning to a palliative approach (Auret, Bulsara, & Joske, 2003; Manitta et al., 2010; McGrath & Holewa, 2007) . Haematologists have cited lack of prognostic tools near the end of life as a hindrance to optimal end-of-life care (Auret et al., 2003) .
A significant gap in knowledge exists about predicting survival near the end of life for people with a haematological malignancy (Button, Chan, Chambers, Butler, & Yates, 2017a,b) . A recent systematic review of prognostic factors present in the final 3 months of life revealed that the body of knowledge is predominantly focused on people who are admitted to the intensive care unit, or are treated aggressively (Button et al., 2017b) . Few studies have explored prognostic factors or prognostic tools to inform transitioning to end-of-life care for people with a haematological malignancy (Button et al., 2017a; Chou et al., 2015; Corbett, Johnstone, McCracken Trauer, & Spruyt, 2013; Kripp et al., 2014; Ohno, Abe, Sasaki, & Okuhiro, 2017) .
Identifying when a person is at risk of deteriorating and dying is vital to facilitate appropriate treatment decisions, patient autonomy, resuscitation planning, advance care planning, and best practice care at the end of life (Highet, Crawford, Murray, & Boyd, 2013) . Accurate identification of risk can allow clinicians (medical, nursing, and allied health) to have honest sensitive conversations with patients and their families around the potential for deterioration and death, while continuing current appropriate care (Dalgaard, Thorsell, & Delmar, 2010; Highet et al., 2013) . This has been referred to as "raining day thinking" or "insurance policy health care" where patients are encouraged to "hope for the best, but prepare for the rest" (Gold Standards Framework, 2011) . This concept has a subtle yet important difference to prognosticating, which typically focuses on predicting time frames of survival (Christakis, 1999; Glare & Sinclair, 2008; Highet et al., 2013) . In contrast, identifying risk of deteriorating and dying focuses on planning for potential needs (Gold Standards Framework, 2011).
| Terminology
The term "deteriorating and dying" was used in this study to align with internationally used language around risk of death for the
Why is this research needed?
• A significant gap in knowledge exists about prognosticating near the end of life for people with a haematological malignancy.
• Few studies have explored prognostic factors or prognostic tools to inform timely integration of palliative care provision and transitioning to end-of-life care in the specialty area of clinical malignant haematology.
What are the key findings?
• This study used the Delphi approach to gather expert consensus about the clinical indicators that signal a person with a haematological malignancy is at risk of deteriorating and dying.
• Consensus was achieved on the following 11 clinical and (k) anorexia and/or weight loss.
• Clinical indicators included in the final results were a combination of subjective and objective markers of deterioration due to the heterogeneity of people with a haematological malignancy.
How should the findings be used to influence policy/practice/research/education?
• The clinical indicators identified in this study can be used • This work has started the conversation about an anticipatory approach to deteriorating and dying for people with a haematological malignancy.
• Further research is warranted to investigate the findings of this study in the clinical setting. purposes of palliative care integration (Highet et al., 2013) . Although widely used, this term is poorly defined in the literature. In this study, the term "deteriorating and dying" refers to when a person is at risk of dying within 3-6 months. This is a shorter time frame than other research focusing on identifying risk of dying which looks at the last 6-12 months (Maas, Murray, Engels, & Campbell, 2013) . This shortened time frame was considered appropriate for people with a haematological malignancy, who often deteriorate rapidly (McGrath & Holewa, 2007) . Additionally, this terminology was used as it is difficult to separate deterioration and death without the benefit of hindsight, particularly for people with a haematological malignancy who often experience episodes of sudden deterioration in their clinical condition, followed by periods of recovery and stability (McGrath & Holewa, 2007) . People who experience clinical deterioration are likely to have physical, psychosocial, or spiritual palliative care needs, regardless of the outcome of the deterioration. For these reasons, the term "deterioration and dying" has been used.
| Conceptual framework
The transdisciplinary model of evidence-based decision-making was the broad conceptual framework that guided this study as it acknowledged the range of appropriate research methods to address a complex clinical question, the contextual nature of decision-making, and the importance of the individual or population (Satterfield et al., 2009) . The model provides a clear and rationale process for clinical decision-making by incorporating the three following domains: (a) best available research evidence; (b) clinical expertise; and (c) the population's characteristics needs, values, and preferences (Satterfield et al., 2009 ). This was the appropriate model to guide this research and to facilitate the translation of evidence into practice.
| Aim
This study aimed to use the Delphi approach to identify clinical indicators that signal a person with a haematological malignancy is at risk of deteriorating and dying by confirming, rejecting, and expanding on the findings of a systematic review of prognostic factors present near the end of life for people with a haematological malignancy.
| DESIGN
We conducted a three-step international modified Delphi approach between September 2015 -March 2016. The Delphi method is an iterative structured process designed to gather opinion from a panel of geographically dispersed expert participants, via a series of surveys (Keeney, Hasson, & McKenna, 2001 ). The approach is an accepted and widely used research method (Hsu & Sanford, 2007) and is said to be growing in popularity, particularly in the area of health sciences due to its ability to explore complex topics (Keeney et al., 2001 ). Although there is no set rule on the number of rounds necessary to achieve consensus, it is often reached within three rounds (Hasson, Keeney, & McKenna, 2000) . Participant anonymity among the panel reduces the influence of persuasive leaders in the group (Hasson et al., 2000) .
The approach was appropriate for this study as it is a validated mixed-method technique for measuring and achieving consensus of opinion on a complex topic where there is limited scientific evidence available (Keeney et al., 2001 ). This study was needed to strengthen and expand on the current body of knowledge about predicting sur- This study aimed to identify clinical indicators rather than prognostic factors as the latter are often focused on estimating the chances of disease recovery, recurrence or death. In this study, clinical indicators were defined as patient outcomes that are markers of risk and improve the quality of patient care, support services, and organizational functions (Mainz, 2003) . Clinical indicators are used to monitor the quality of health care and to create the basis for improvement and prioritization in health care.
| Participants
An international panel of haematology and palliative care medical specialists and advanced practice nurses were selected to participate.
Purposive sampling, which was criteria based, was used to select the exists to select experts who will be relatively impartial on the topic, yet also be interested enough in the research topic to participate to completion (Hasson et al., 2000) . Variation in our sampling techniques enhanced the representativeness of the sample and reduced bias associated with a non-random sample, which is a key criticism of the method (Hasson et al., 2000; Keeney et al., 2001) . | 163 interest in participating in the study, they were then contacted by the researcher for further information to ensure they met the selection criteria.
| Analysis and statistical methods
Opinions of participants were captured using a seven-point Likerttype scale which ranged from "1 = entirely disagree" -"7 = entirely agree". Consensus on an item was defined a priori and was considered to be achieved if at least 70% of participants' responses fell within two side-by-side points on a seven-point Likert-type scale Open-ended data were transcribed into a Microsoft Office Excel spreadsheet to allow for movement and filtering. Open-ended data in the Delphi method are best analysed via a simple process of content analysis (Keeney et al., 2011) . Therefore, open-ended data were subjected to a process of content analysis using a modified version of Burnard's 14-step process (Burnard, 1991) . Not all steps in Burnard's process were relevant to this study. Hence, qualitative analysis was modified to meet the specific needs of this study and was justified accordingly. An outline of the content analysis is presented in Table 1 with comparison to Burnard's process. This method of content analysis was followed consistently and rigorously. Themes and statements to emerge from open-ended data provided context and allowed each indicator to be modified, collapsed or excluded.
Between rounds, each clinical indicator was also explored in the light of the relevant literature and critically reviewed according to the study aims.
| Rigour
Implementation of the Delphi method requires a high level of "methodological precision" (Hasson et al., 2000) . The key weaknesses, potential issues, and limitations include a low response rate of the panel, consumption of large blocks of time, the lack of validity and reliability, the inappropriate selection of experts, the anonymity of participants, a rigid questionnaire design, subjective data analysis, and the potential for consensus of general statements rather than specific information (Hsu & Sanford, 2007; Keeney et al., 2001; Keeney, Hasson, & McKenna, 2006) . These issues were carefully considered by the research team and recommendations published by T A B L E 1 Burnard's process of content analysis used in this study
Step Burnard's process Modification for this study seminal authors in the field were followed when designing the protocol and undertaking this study (Hasson et al., 2000; Hsu & Sanford, 2007; Keeney et al., 2006) . Steps were taken to enhance the rigour of the approach. Selection of participants was performed judiciously as it is a crucial step in the Delphi approach (Hsu & Sanford, 2007) . A second reviewer (NG) independently performed the steps of content analysis (Burnard, 1991) . All decisions made in the study were reviewed by a second member of the research team. A detailed decision-making trail was kept by the research team to enhance the transparency and rigour of the approach.
| Methodology of the Delphi process
The methodology of the Delphi approach used in this study is displayed in Figure 1 .
| Round 1
The panel was asked to review and expand on the findings of a systematic review of prognostic factors present in the final 3 months of life for people with a haematological malignancy (Button et al., 2017b) . Twenty-seven indicators were presented to the panel who was asked to provide a numerical rating on the extent they felt these indicators were associated with deteriorating and dying within 3-6 months. They were also asked to provide open-ended responses about each indicator and suggest new clinical indicators.
| Round 2
The panel was informed of the results of the Round 1 survey including the median score, IQR, the consensus rating, and the associated 
| Round 3
The 
| Ethical considerations
The study was approved by the appropriate hospital ethics committees: HREC/15/QRBW/289 and received administrative approval by the university ethics committee. Participants provided informed consent and anonymity was ensured throughout the study and on completion.
| RESULTS

| Participants
During the recruitment phase, 31 individuals returned signed consent forms. All participants had over 5 years' experience in advanced roles working directly with people with a range of haematological malignancies (i.e., leukaemia, lymphoma, myeloma, stem cell transplantation) throughout the illness trajectory. Only one participant worked solely with one tumour stream (lymphoma). Many participants had published widely around palliative care for people with a haematological malignancy. Characteristics of the panel are displayed in Table 2 .
| Delphi process
Throughout the three rounds of survey distribution, response rates were maintained at 84% (N = 27). A flow chart of the Delphi processes of achieving consensus is displayed in Figure 2 .
| Round 1
Of emerged from the open-ended text were (anonymously) carried into Round 2 to be voted on by the group, regardless of who suggested it, or how frequent it was suggested. This was done to ensure all comments from the panel were treated with equal importance and were given the opportunity to be reviewed. 
| Round 3
One clinical indicator and two themes and statements achieved consensus for inclusion in the final results. One indicator did not achieve consensus and remains undecided as being associated with deteriorating and dying; distress. 
| Final results
| Additional findings
Several key findings were made in addition to the identification of clinical indicators. These findings value-added to the aims of the study by providing context and a more complex understanding of the clinical Table 4 ), to identify risk of deteriorating and dying. This was in contrast to the prognostic factors identified in the systematic review that informed the Round 1 survey (Button et al., 2017b) . These studies predominantly focused on objective or laboratory-based indicators derived from blood test results or definitions of organ failure (Button et al., 2017b ). This move is reflected well in one participants' comment following the Round 1 survey: "More specific clinical criteria that are disease-based High care
Clinical indicators presented a Clinical indicators that achieved consensus for inclusionincluded in final results
T A B L E 4 Collective response, degree of agreement, consensus rating, and associated themes and statements for clinical indicators included in final results
Items rated by expert panel
Need for ongoing high level of care at home or in nursing home or other high care facility (excluding short stay for rehabilitation) This was keeping in line with similar work in this area where clinical indicators that identify risk of dying in the cancer and non-cancer population are also subjective in nature and harness the power of clinician judgement (Maas et al., 2013) . This is the first study to take this approach to identifying risk of deteriorating and dying in the haematology setting.
A strength of this study is that the expert panel refined the clinical indicators over the three rounds with their knowledge of the specific diseases, the fluctuating illness trajectory of haematological malignancies and reversible nature of many complications. This is an important finding in this study as previous studies on prognosticating for people with a haematological malignancy near the end of life have tested variables that are somewhat blunt measures if not adequately contextualized for the haematology population (Button et al., 2017b This work significantly adds to the body of knowledge as the findings of this study confirm and build on the few studies that have explored prognosticating near the end of life for people with a haematological malignancy to inform palliative and end-of-life care. Chou et al. (2015) found that the palliative prognostic index (PPI) was a useful prognosticator of life expectancy in "terminally ill" people (inpatients and outpatients) with haematological malignancies known to a specialist palliative care service (median survival of 16 days, IQR 4-4.75 days) in Taiwan. The core components of the PPI include performance status, dyspnoea, delirium, oral intake, and oedema (Chou et al., 2015) . Our findings corroborate performance status and oral intake, but not the remaining components of the PPI. Ohno et al. (2017) reported that the PPI was predictive of mortality in people with a haematological malignancy admitted to a haematology unit (median survival of 6.4 weeks) in Japan. Additionally, these authors found a prognostic model developed by Kripp et al. (2014) was also significantly predictive of mortality for people in a palliative care unit (inpatient hospice) in Germany categorized in a "high risk" group (Ohno et al., 2017) . This model included low performance status, requiring opioid analgesia, low platelet count, low albumin levels, and high lactate dehydrogenase levels (Kripp et al., 2014) . This study significantly builds on previous work as neither of these two studies assessed the importance of advanced or relapsed disease. While performance status and oral intake were present in final results of this study, dyspnoea, delirium, oedema, lactate dehydrogenase, platelet count, and albumin levels were excluded, modified or collapsed following on from Round 1. This could be attributed to the Chou et al. (2015) and Ohno et al. (2017) studies having shorter time frames of survival in their populations (16 days and 6.4 weeks respectively) than was the aim of this study, to identify risk of deteriorating and dying within 3-6 months. Our study provides valuable findings that can facilitate anticipatory care planning prior to the final days to weeks of life.
To date, limited literature has explored an appropriate time to plan and prepare patients with a haematological malignancy for potential deterioration and death and their carers (Button et al., 2017a) . This study has created new knowledge on this topic to inform clinical practice. Additionally, this work has started the conversation about an anticipatory approach to deteriorating and dying for people with a BUTTON ET AL.
| 171 haematological malignancy. This approach is appropriate for this population due to the fluctuating and unpredictable illness trajectory they often experience with potential for rapid deterioration to a terminal event (Hung et al., 2013; Manitta et al., 2010; McGrath & Holewa, 2007) .
This study is a stand-alone piece in a larger programme of work that has begun to address a gap in knowledge. Limited literature has explored predicting survival near the end of life for people with a haematological malignancy to inform palliative care provision and transitioning to end-of-life care (Manitta et al., 2010) . This Delphi approach was conducted following a systematic review of prognostic factors in the final 3 months of life for people with a haematological malignancy which identified significant gaps and limitations in the body of knowledge (Button et al., 2017b) . Following on from this Delphi, a case-control study was conducted to test the clinical indicators identified by the expert panel (currently under review). The findings of the case-control study will inform the development of a clinical tool to identify risk of deteriorating and dying for people with a haematological malignancy. This work will require prospective testing in the clinical setting and will be the next phase of this programme of research.
| Strengths and limitations
It is acknowledged that this study has limitations. Although interna- there is evidence that supports clinician judgement as a valuable method of identifying risk of dying to inform palliative and end-of-life care planning (Maltoni et al., 2005; Mitchell et al., 2017) . The iterative group process of the Delphi approach strengthened individual clinician judgement through the three iterations and group "discussion". Additionally, the Delphi approach was an appropriate method for this study as limited literature existed on this complex topic (Keeney et al., 2001 (Keeney et al., , 2006 . It was a valuable method to use to create preliminary knowledge. Although preliminary, the findings of this study are valuable as they are the best available evidence to date about identifying risk of dying within 3-6 months for people with a haematological malignancy and can be used in combination with clinical judgement. dying. This can lead to collaborative discussions around goals of care, resuscitation planning, advance care planning, referral to specialist palliative care services (if this has not already occurred) and planning for possible death; and ultimately increase patient autonomy (Highet et al., 2013; Maas et al., 2013; Nightingale, Monsell, Wong, & Cheung, 2011 haematological malignancy and act as a prompt for clinician intuition.
| CONCLUSION
The findings of this Delphi can inform discussions around risk of deteriorating and dying and anticipatory care planning as they present the best available expert opinion on the topic. The findings of this study can help to guide clinicians on how to give patients more control over their death and the time they have remaining.
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